Securities code: 603122 securities abbreviation: Hefu China Announcement No.: pro 2022004 Hefu (China) Medical Technology Co., Ltd
Stock trading abnormal fluctuations and risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
1. The stock price of Hefu (China) Medical Technology Co., Ltd. (hereinafter referred to as “the company”) has increased significantly recently. From February 16 to March 3, 2022, the limit has been raised for 11 consecutive trading days (except the first day). The company specially reminds investors to pay attention to the trading risks in the secondary market.
2. The P / E ratio of the company is relatively high. According to wind data, as of March 3, 2022, the static P / E ratio of the company is 94.25 and the rolling P / E ratio of the company is 83.15. According to the industry data released on the website of China Securities Index Co., Ltd. as of March 3, 2022, the static P / E ratio of the wholesale industry to which the company belongs is 18.83 and the rolling P / E ratio is 16.44, Investors should pay attention to transaction risks.
Investors are requested to fully read the relevant risk matters stated in the body of this announcement. The company specially reminds investors to invest rationally.
1、 Details of stock trading (abnormal) fluctuations
The deviation of the daily closing price increase of the company’s stock price in two consecutive trading days on March 2 and March 3, 2022 is more than 20%. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to the abnormal fluctuation of stock trading price.
2、 Relevant information concerned and verified by the company
(I) operation
According to the company’s self inspection, the company’s daily business activities are normal, the market environment and industrial policies have not been significantly adjusted, the production cost and sales have not fluctuated significantly, the internal production and operation order is normal, and the internal and external business environment of the company has not changed significantly.
(II) major events
After self inspection by the company and verification with the controlling shareholder Hefu (Hong Kong) Holding Co., Ltd. (hereinafter referred to as “Hefu Hong Kong”) and the indirect controlling shareholder Cowealth medical Holding Co., Ltd. (hereinafter referred to as “Hefu holding”), as of the disclosure date of this announcement, in addition to the information publicly disclosed on the designated media, There are no major matters affecting the abnormal fluctuation of the company’s stock trading price; The company’s major assets that should not be disclosed, such as the company’s major asset acquisition, reorganization, share issuance, reorganization, and other major assets that should not be disclosed, but should not be limited to the company’s major assets that should not be disclosed, such as the company’s share acquisition, reorganization, and other strategic assets that should not be disclosed.
(III) media reports, market rumors and hot concepts
After verification, as of the disclosure date of this announcement, the company has not found any media reports or market rumors and matters involving the concept of hot spots that may or have had an impact on the trading price of the company’s shares.
(IV) other stock price sensitive information
After verification, the company has not found any other major events that may have a great impact on the company’s stock price, and the company’s directors, supervisors, senior managers, controlling shareholders, indirect controlling shareholders and other important shareholders did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that as of the disclosure date of this announcement, the company has no undisclosed matters or planning, negotiation, intention and agreement related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange; The board of directors has not been informed that the company has information that should be disclosed but has not been disclosed in accordance with relevant provisions such as the Listing Rules of Shanghai Stock Exchange, which has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
3、 Relevant risk tips
The stock price has increased significantly recently. From February 16 to March 3, 2022, the limit has been raised for 11 consecutive trading days (except the first day), and the cumulative increase in 11 trading days has reached 284.91%. The company specially reminds investors to pay attention to the trading risks in the secondary market.
1. Risk of high P / E ratio of the company
The P / E ratio of the company is relatively high. According to wind data, as of March 3, 2022, the static P / E ratio of the company is 94.25 and the rolling P / E ratio of the company is 83.15. According to the industry data released on the website of China Securities Index Co., Ltd. as of March 3, 2022, the static P / E ratio of the wholesale industry to which the company belongs is 18.83 and the rolling P / E ratio is 16.44. Investors should pay attention to transaction risks.
As of March 3, 2022, select listed companies close to the company’s main business for price earnings ratio comparison, as follows:
Serial number securities code securities abbreviation static P / E ratio dynamic P / E ratio
1 Shanghai Runda Medical Technology Co.Ltd(603108) . SH Shanghai Runda Medical Technology Co.Ltd(603108) 20.71 16.28
Company 94.25 83.15
Note: the data comes from wind
As of March 3, 2022, the company’s rolling P / E ratio is higher than the average value of the above listed companies, while the static P / E ratio is significantly higher than the average value of the above listed companies. Investors should pay attention to transaction risks.
2. Risk of intensified market competition
In recent years, the in vitro diagnosis industry has become one of the rapidly developing fields in China’s medical and health industry. The increasing market demand and the encouragement of national policies will attract more manufacturers to enter, and the market competition will further intensify. If the company cannot continuously improve its product layout, sales and service network in the future, the fierce market competition environment may have an adverse impact on the company’s production, operation and profitability.
3. Epidemic risk of new pneumonia
As the epidemic situation has not yet fundamentally ended, the epidemic prevention work still needs to be continued. In the future, if the New Coronavirus pneumonia epidemic prevention effect in China is not sustainable or affected by COVID-19 pneumonia outside the country, the downstream medical institutions will concentrate on the treatment of COVID-19 pneumonia patients. In order to avoid cross infection in hospitals, the number of regular visits in hospitals will be reduced, which will lead to a reduction in consumption of reagent consumables routinely. May adversely affect the company’s operating performance.
The company solemnly reminds investors that Shanghai Securities News, China Securities News, securities times and Securities Daily are the designated information disclosure newspapers of the company, and the website of Shanghai Stock Exchange (www.sse. Com. CN.) Specify an information disclosure website for the company. All information of the company shall be subject to the information published in the above designated media. Please pay attention to investment risks.
It is hereby announced.
Board of directors of Hefu (China) Medical Technology Co., Ltd. March 4, 2022
